Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Diltiazem

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Cardizem ® -diltiazem (opens in a new tab)Original source URL: https://globalrph.com/dilution/cardizem-diltiazem/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/cardizem-diltiazem/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:44:42.317408+00:00
Source location
div.post-content
Packaged content SHA-256
3ff458855062742d3e234ce1b5708467f8d7ab3c73cf99485cd0c7f14915f2a9
Original response SHA-256
0bd72f55328e0646ba9d6ad906e965155087940f2fdd6540a08f88a9d238c397
Source body SHA-256
059dc1bab27f3f1283fb3a367905ed06017d794c6ebe6fcaf8e3c916e7af7b94

DILTIAZEM (CARDIZEM ®)
The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents
D5W, NS

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]
---Final Concentration 1 mg/ml ---
Diltiazem hydrochloride Solution (5 mg/mL)
[125 mg (25 ml)/ 100 ml] [Titrate]
[Total volume = 125 ml]

-----------------------------------------

Diltiazem hydrochloride powder, for solution (100mg vials)
[100mg / 100 ml] [Titrate]
[Total volume = 100 ml]

The vials contain sterile diltiazem hydrochloride, USP, 100 mg and mannitol, USP, 75 mg base for reconstitution in the ADD-Vantage®Flexible Diluent Container containing 5% dextrose injection or 0.9% sodium chloride injection.

Note: if the ADD-Vantage®Flexible containers are not available use the following steps:

  1. remove the breakaway vial cap and the vial port cover from the 100mg vial.
  2. withdraw 5 to 10 ml from a 100mL bag of D5W or NS
  3. Swirl the container to dissolve the diltiazem hcl powder [MAINTAINING STRICT ASEPTIC TECHIQUE IS CRITICAL].
  4. Withdraw the contents and inject into the 100mL bag and use within 24 hours.

Stability / Miscellaneous

ASHP® Injectable Drug Information™. 2021 Edition. A Comprehensive Guide to Compatibility and Stability.
DOI: https://doi.org/10.37573/9781585286850

Diltiazem hydrochloride 1 g/L (1 mg/mL) in dextrose 5% and in sodium chloride 0.9% was evaluated for loss due to sorption to a variety of polymer container types compared to glass containers. No significant loss due to sorption was found at 21°C after 48 hours of contact time to PVC and polyethylene containers and 24 hours of contact time to polyamide containers.

Stability data:
Drug Stability
Refrigerated		 Stability
Room Temp.		 Reconstituted
Vial/Powder		 Notes
Diltiazem - Cardizem Store under refrigeration 2° to 8°C (36° to 46°F).

Stable in the following parenteral solutions for at least 24 hours when stored in glass or polyvinylchloride (PVC) bags under refrigeration 2° to 8°C (36° to 46°F).
dextrose (5%) injection USP
sodium chloride (0.9%) injection USP
dextrose (5%) and sodium chloride (0.45%) injection USP

May be stored at room temperature for up to 1 month. Destroy after 1 month at room temperature.

Stable in the following parenteral solutions for at least 24 hours when stored in glass or polyvinylchloride (PVC) bags at controlled room temperature 15° to 30°C (59° to 86°F) dextrose (5%) injection USP
sodium chloride (0.9%) injection USP
dextrose (5%) and sodium chloride (0.45%) injection USP

Solution Parental drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Do not freeze.

Diltiazem hydrochloride injection was found to be physically compatible and chemically stable in the following parenteral solutions for at least 24 hours when stored in glass or polyvinylchloride (PVC) bags at controlled room temperature 20 to 25°C (68 to 77°F) [see USP] or under refrigeration 2 to 8°C (36 to 46°F).

• dextrose (5%) injection USP
• sodium chloride (0.9%) injection USP
• dextrose (5%) and sodium chloride (0.45%) injection USP
Label: Refrigerate/ concentration= 1 mg/ ml.

DOSAGE AND ADMINISTRATION
Direct Intravenous Single Injections (Bolus)
The initial dose of Diltiazem Hydrochloride Injection should be 0.25 mg/kg actual body weight as a bolus administered over 2 minutes (20 mg is a reasonable dose for the average patient). If response is inadequate, a second dose may be administered after 15 minutes. The second bolus dose of diltiazem hydrochloride injection should be 0.35 mg/kg actual body weight administered over 2 minutes (25 mg is a reasonable dose for the average patient). Subsequent intravenous bolus doses should be individualized for each patient. Patients with low body weights should be dosed on a mg/kg basis. Some patients may respond to an initial dose of 0.15 mg/kg, although duration of action may be shorter. Experience with this dose is limited.

Continuous Intravenous Infusion
For continued reduction of the heart rate (up to 24 hours) in patients with atrial fibrillation or atrial flutter, an intravenous infusion of diltiazem hydrochloride may be administered. Immediately following bolus administration of 20 mg (0.25 mg/kg) or 25 mg (0.35 mg/kg) diltiazem hydrochloride injection and reduction of heart rate, begin an intravenous infusion of diltiazem hydrochloride. The recommended initial infusion rate of diltiazem hydrochloride is 10 mg/h. Some patients may maintain response to an initial rate of 5 mg/h. The infusion rate may be increased in 5 mg/h increments up to 15 mg/h as needed, if further reduction in heart rate is required. The infusion may be maintained for up to 24 hours.

Diltiazem shows dose-dependent, non-linear pharmacokinetics. Duration of infusion longer than 24 hours and infusion rates greater than 15 mg/h have not been studied. Therefore, infusion duration exceeding 24 hours and infusion rates exceeding 15 mg/h are not recommended.

Dilution: To prepare diltiazem hydrochloride injection for continuous intravenous infusion aseptically transfer the appropriate quantity (see chart) of diltiazem hydrochloride injection to the desired volume of either Normal Saline, D5W, or D5W/0.45% NaCl. Mix thoroughly. Use within 24 hours. Keep refrigerated until use.

Diluent Volume Quantity of Diltiazem HCl Injection to Add Final Concentration Administration Dose* Infusion Rate
100 mL 125 mg (25 mL)

Final Volume 125 mL

 1 mg/mL 10 mg/h

15 mg/h

 10 mL/h

15 mL/h
250 mL 250 mg (50 mL)

Final Volume 300 mL

 0.83 mg/mL 10 mg/h

15 mg/h

 12 mL/h

18 mL/h
500 mL 250 mg (50 mL) 0.45 mg/mL 10 mg/h 22 mL/h
Final Volume 550 mL 15 mg/h 33 mL/h

*5 mg/h may be appropriate for some patients.

Compatibility:
Diltiazem hydrochloride injection was tested for compatibility with three commonly used intravenous fluids at a maximal concentration of 1 mg diltiazem hydrochloride per milliliter. Diltiazem hydrochloride injection was found to be physically compatible and chemically stable in the following parenteral solutions for at least 24 hours when stored in glass or polyvinylchloride (PVC) bags at controlled room temperature 20 to 25°C (68 to 77°F) [see USP] or under refrigeration 2 to 8°C (36 to 46°F).

• dextrose (5%) injection USP
• sodium chloride (0.9%) injection USP
• dextrose (5%) and sodium chloride (0.45%) injection USP

Physical Incompatibilities:
Because of potential physical incompatibilities, it is recommended that diltiazem hydrochloride not be mixed with any other drugs in the same container. If possible, it is recommended that diltiazem hydrochloride not be coinfused in the same intravenous line. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Diltiazem Hydrochloride. Physical incompatibilities (precipitate formation or cloudiness) were observed when diltiazem hydrochloride was infused in the same intravenous line with the following drugs: acetazolamide, acyclovir, aminophylline, ampicillin, ampicillin sodium/sulbactam sodium, cefamandole, cefoperazone, diazepam, furosemide, hydrocortisone sodium succinate, insulin, (regular: 100 units/mL), methylprednisolone sodium succinate, mezlocillin, nafcillin, phenytoin, rifampin, and sodium bicarbonate.

Transition to Further Antiarrhythmic Therapy:
Transition to other antiarrhythmic agents following administration of diltiazem hydrochloride injection is generally safe. However, reference should be made to the respective agent manufacturer's package insert for information relative to dosage and administration.

In controlled clinical trials, therapy with antiarrhythmic agents to maintain reduced heart rate in atrial fibrillation or atrial flutter or for prophylaxis of PSVT was generally started within 3 hours after bolus administration of diltiazem. These antiarrhythmic agents were intravenous or oral digoxin, Class 1 antiarrhythmics (e.g., quinidine, procainamide), calcium channel blockers, and oral beta-blockers.

Experience in the use of antiarrhythmic agents following maintenance infusion of diltiazem hydrochloride injection is limited. Patients should be dosed on an individual basis and reference should be made to the respective manufacturer's package insert for information relative to dosage and administration.

HOW SUPPLIED
Diltiazem Hydrochloride Injection is supplied in single-dose containers as follows:
10 Fliptop Vials/Carton - 10 mL
10 Fliptop Vials/Carton - 5 mL
---------------------
Fliptop Vials - 25 mL
---------------------
Powder:
NDC No. Container Size
0409-4350-03 [10 ADD-Vantage® Vials/Tray] 100 mg
---------------------

DISCARD UNUSED PORTION.

STORE PRODUCT UNDER REFRIGERATION 2 TO 8°C (36 TO 46°F). DO NOT FREEZE.

MAY BE STORED AT ROOM TEMPERATURE FOR UP TO 1 MONTH. DESTROY AFTER 1 MONTH AT ROOM TEMPERATURE.

Revised: June, 2006
©Hospira 2006 EN-1220 Printed in USA
HOSPIRA, INC., LAKE FOREST, IL 60045 USA

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
no_routine_adjustment_identified
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      diltiazem
      Source IDH51-85322D40A0988000C9A1AB83
      Generic name
      Diltiazem
      Source IDH51-D6957EB5B768EB04AC5553F1
      Class
      Cardiovascular and vasoactive
      Source IDH51-84E0F91DCDB6360AE0BE7FD7
      Subclass
      Non-dihydropyridine calcium-channel blocker
      Source IDH51-B6C6253764BEBBE2BD4D234C
      Primary uses
      1. Atrial fibrillation/flutter rate control
        Source IDH51-EFE04100B3ABEE1BD4454B4B
      2. Selected supraventricular tachycardia
        Source IDH51-FC6083CD598029218480CDF5
      Mechanism
      Blocks L-type calcium channels, slows AV nodal conduction, and reduces contractility with variable vasodilation.
      Source IDH51-F36EF4A84BE70AAE88A2D2BA
      Mechanism level
      drug_specific
      Source IDH51-EFE049950E9527B20BC5FA99
      Basic dosing orientation
      Adult continuous infusion | Existing preparation record; use current package insert for indication-specific selection | Common bag 125 mg | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Adult | 0.25 mg/kg first bolus; 0.35 mg/kg second bolus if indicated | 0.25 mg/kg first bolus; 0.35 mg/kg second bolus if indicated | Patient- and indication-specific | See current package insert | IV push
      Source IDH51-CC87F70F82049BBE8E8F5840
      Administration orientation
      5 to 15 mg/hour after bolus; Over 2 minutes; 5 mg/mL may be given undiluted or diluted per policy; Over 2 minutes
      Source IDH51-71AD0330B5C2017175739170
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)No routine renal adjustment is commonly used for many indications, but verify the current label and clinical context.
      Source IDH51-4A9B974646C28D676A785160
      Key safety orientation
      1. Hypotension, bradycardia, heart block, and worsening heart failure.
        Source IDH51-191EF70A7CC522A1046EC7AF
      2. Do not use for pre-excited atrial fibrillation.
        Source IDH51-7F88768F26013127A8EA82C6
      Coverage path
      structured_local_snapshot
      Source IDH51-C69FDC27EEFB322CD38A63F3
      Coverage path label
      Structured GlobalRPh route snapshot
      Source IDH51-44068C8620818385072D67C1
      Legacy title
      Diltiazem (Cardizem)
      Source IDH51-CDFFE1C8E8F579FB81CB5970
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-3CB788F3F33DE66F26D5A75B
      Search text
      Diltiazem Cardiovascular and vasoactive Non-dihydropyridine calcium-channel blocker Atrial fibrillation/flutter rate control Selected supraventricular tachycardia Blocks L-type calcium channels, slows AV nodal conduction, and reduces contractility with variable vasodilation. Adult continuous infusion | Existing preparation record; use current package insert for indication-specific selection | Common bag 125 mg | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Adult | 0.25 mg/kg first bolus; 0.35 mg/kg second bolus if indicated | 0.25 mg/kg first bolus; 0.35 mg/kg second bolus if indicated | Patient- and indication-specific | See current package insert | IV push 5 to 15 mg/hour after bolus; Over 2 minutes; 5 mg/mL may be given undiluted or diluted per policy; Over 2 minutes No routine renal adjustment is commonly used for many indications, but verify the current label and clinical context. Hypotension, bradycardia, heart block, and worsening heart failure. Do not use for pre-excited atrial fibrillation. Structured GlobalRPh route snapshot
      Source IDH51-7D795909AB365512025AE0D0
      Official access mode
      search
      Source IDH51-C794DABE745364C1F059FD61
      Official search query
      Diltiazem
      Source IDH51-5EDA07026A9A3166C03CEC28
      Official access reason
      A source-backed DailyMed search is available; select and confirm the exact IV product.
      Source IDH51-6435557ABCA418B9C02117A5

      No separate structured rows were bundled for dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical dilution and intermittent infusion preparation

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationAmountReconstitutionDiluentFinal volumeConcentrationRateStabilityNotes
      Source IDH51-894A242AF77A8BCE78C8177F
      Adult continuous infusion
      Source IDH51-4F92BB792C5DA3F27FA1AD00
      		Common bag 125 mg
      Source IDH51-CEB44268D857D33785A96FBD
      		Add concentrate to compatible solution or use premix.
      Source IDH51-D37B717F8F6B24A14423917A
      		NS or D5W
      Source IDH51-3FB41C040B662BA5ACDC4B6E
      		125 mL
      Source IDH51-30866CBA222158DDBA36FF54
      		1 mg/mL
      Source IDH51-B46F13A42A267B1E69F93B3E
      		5 to 15 mg/hour after bolus
      Source IDH51-83683C27339A57DD2C4A3170
      		Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-85DC3480CDB6D4766E50E949
      		Avoid in pre-excited atrial fibrillation and severe LV systolic dysfunction unless specialist-directed.
      Source IDH51-BCC160C1D3B59E83792F8EC0

      Historical IV-push guidance

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationDose scopeConcentrationRateStatusNotes
      Source IDH51-5E18093CF63570A4641A0AC9
      Adult
      Source IDH51-7CA9C58A07EF48EBA7C95D46
      		0.25 mg/kg first bolus; 0.35 mg/kg second bolus if indicated
      Source IDH51-F9E935596BD7923BC97DF109
      		5 mg/mL may be given undiluted or diluted per policy
      Source IDH51-5AB3C0CBE52F634B3B30500C
      		Over 2 minutes
      Source IDH51-4E6B49B8B8C756E6AF833CAE
      		Label-standard with monitoring
      Source IDH51-168AFC2966BF961AD7926604
      		Continuous ECG and frequent blood pressure measurement required.
      Source IDH51-5EA2290440BF65C570954D9C

      Historical continuous-infusion guidance

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationStandard concentrationInitial rateTitrationMaximumNotes
      Source IDH51-CDD6CDCAD74BFFE2CD835C20
      Adult
      Source IDH51-AD0257DB2F74E726B7B5245D
      		125 mg/125 mL (1 mg/mL)
      Source IDH51-30535B4D7529A2BF2A7B9A88
      		5 to 10 mg/hour
      Source IDH51-907584463051B36A81E9F617
      		Titrate to ventricular rate
      Source IDH51-0BC71D03B909FA4D4E35F4B4
      		15 mg/hour commonly
      Source IDH51-1B30AA2180298B8B0C2ADF09
      		Duration and transition plan should be explicit.
      Source IDH51-1B61B43C30A57E5A62DC4DCD

      Historical indication and population dosing

      Recovered tables and source-separated snapshots; full clinical revalidation remains pending.

      Existing dose and route snapshots

      RoutePopulationIndicationDoseIntervalDurationAdministrationSource levelNotes
      Source IDH51-1C270C8E5A98B9B435A92001
      IV infusion
      Source IDH51-FACBFF6353B67369F61D50DD
      		Adult continuous infusion
      Source IDH51-DDAE0A8391A6B620DAE4D703
      		Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-52B6D8245A2BA7FF2CE3C20A
      		Common bag 125 mg
      Source IDH51-6DBB71BD1BEF4D45EFD6FFF2
      		Not normalized in the preparation record
      Source IDH51-D6B6812FF0B5E5160874AAB3
      		See current package insert and professional guidance
      Source IDH51-994EBC532C11F1DB48CCC234
      		5 to 15 mg/hour after bolus
      Source IDH51-3AE297A366C01B16D7DF85E0
      		Existing GlobalRPh structured preparation snapshot
      Source IDH51-F45CBC843061B94B0C92A402
      		Avoid in pre-excited atrial fibrillation and severe LV systolic dysfunction unless specialist-directed.
      Source IDH51-ED353FE7186C6C405C355E80
      Source IDH51-B7649B3509EA42F3723C7F22
      IV push
      Source IDH51-C27F3449839FCD19E13F5CA6
      		Adult
      Source IDH51-101E53C2431CF39263AB40EA
      		0.25 mg/kg first bolus; 0.35 mg/kg second bolus if indicated
      Source IDH51-090344C2C507C6C272247AE0
      		0.25 mg/kg first bolus; 0.35 mg/kg second bolus if indicated
      Source IDH51-FA1FF1566F83BEAC33E4A327
      		Patient- and indication-specific
      Source IDH51-CC51EED7970E14446C614158
      		See current package insert
      Source IDH51-5A5D34CEA00C14E87106793E
      		Over 2 minutes
      Source IDH51-E5B81E9F078B23F862BA2C5C
      		Existing GlobalRPh IV push snapshot
      Source IDH51-542409850CBBD695008F2E19
      		Label-standard with monitoring Continuous ECG and frequent blood pressure measurement required.
      Source IDH51-726578B89F9A49156D412A3C
      Source IDH51-08FE545C06B0CCEE38B486DC
      Continuous IV infusion
      Source IDH51-0E737CCA1A11F57CC29CCB00
      		Adult
      Source IDH51-1AF18422211B90A9E4799500
      		Existing continuous-infusion record
      Source IDH51-21AD94F02D914D784D65EBEE
      		5 to 10 mg/hour
      Source IDH51-255F225CBA87213584ECA126
      		Continuous infusion; titration-specific
      Source IDH51-5A3080819E1E35AA2B702828
      		Clinical-response dependent
      Source IDH51-0E3207506ECFFFE28D352C92
      		Titrate to ventricular rate
      Source IDH51-29E2C6D8C3306AC0AE111248
      		Existing GlobalRPh continuous-infusion snapshot
      Source IDH51-3DF29544A3656453ED7A5F6D
      		15 mg/hour commonly Duration and transition plan should be explicit.
      Source IDH51-F9FB8CF63D1DDC89095C14C8

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      no_routine_adjustment_identified
      Source IDH51-A239F239096BA9B82A3F22FD
      Summary
      No routine renal adjustment is commonly used for many indications, but verify the current label and clinical context.
      Source IDH51-5F01A0D3A6B697F45A5E7BAA
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-6A3CB7B618F497E12F8D27BF

      Historical Common IV uses

      Recovered v5.1 source content; historical, awaiting current review.

      1. Atrial fibrillation/flutter rate control
        Source IDH51-7A8B9ECD046F507181AAB632
      2. Selected supraventricular tachycardia
        Source IDH51-9294FC56A050FAF200EA7F7F

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Hypotension, bradycardia, heart block, and worsening heart failure.
        Source IDH51-06DA9F5033092875461CAA63
      2. Do not use for pre-excited atrial fibrillation.
        Source IDH51-EA45F38C6A2DF81BF9FE8E37

      Historical Monitoring

      Recovered v5.1 source content; historical, awaiting current review.

      1. Continuous ECG
        Source IDH51-A920907EE62A8F06B57FA4EA
      2. Blood pressure
        Source IDH51-9F06596BF9845C40D919BAEF
      3. Signs of heart failure
        Source IDH51-7DBAA6310DB9BDB4D3569837
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      diltiazem
      Source IDH51-3B63A073F2FB8851F7522EBE
      Generic name
      Diltiazem
      Source IDH51-64B3066BDC1D687BA6A96B52
      Brand names
      1. Cardizem
        Source IDH51-47AB7CA817F89AFC340695B5
      Class
      Cardiovascular and vasoactive
      Source IDH51-BDBA39406FF672AEEC1F8677
      Subclass
      Non-dihydropyridine calcium-channel blocker
      Source IDH51-A7538F0D52D428C42ACEA2D7
      Summary
      IV bolus and infusion for selected supraventricular tachyarrhythmias with continuous ECG and blood-pressure monitoring.
      Source IDH51-B31E9DABEE665B6EB987631D
      Populations
      1. Adult
        Source IDH51-151C220FD94B7D4F755E6BBA
      Evidence tier
      Core reference - verify current label
      Source IDH51-EDD74232823C6A30757D8210
      High alert
      true
      Source IDH51-2E8B62DCF732AD99BCF4CC33
      Hazardous
      false
      Source IDH51-59D025CEBB2219FF5361BA3C
      Status
      Active
      Source IDH51-86D54DF9649822E5D580918B
      Reviewed
      2026-08-29
      Source IDH51-BCE032411DFEB5CF81B44110
      Version added
      1.0
      Source IDH51-686005CDA7C7A5D10931FC22
      Sources
      LabelUrlKind
      Source IDH51-A61C93F7618D7CADC28F02B1
      DailyMed label search
      Source IDH51-13E5828B5919FCFDB0C7DAD6
      		https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Diltiazem (opens in a new tab)
      Source IDH51-45B758C5EB10FA6C4AEC3558
      		Primary
      Source IDH51-8F25921C5E55616463938299
      Source IDH51-E9BEA47B9D3BD48AC043953A
      GlobalRPh legacy IV dilution monograph
      Source IDH51-7D0CF3CAF5961A4105246DF3
      		legacy:auto
      Source IDH51-7EFDC2D363166632BC4F23E2
      		Legacy
      Source IDH51-01345D68DEE568837B658F2A
      Legacy title
      Diltiazem (Cardizem)
      Source IDH51-182710E2A3E5DA3D86082E43
      Clinical release verification
      Audit version
      3.4
      Source IDH51-DE89F0FB3C522FC76EA4386A
      Audited on
      2026-08-30
      Source IDH51-81DCD827A147A2CE3072B164
      Level
      amber
      Source IDH51-15244A997AC1279B8FCDC03B
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-9AC5C98230D7645D28C63EE5
      Exact current label candidate
      false
      Source IDH51-BCCBF428872FB633E2E0D4AF
      Numeric support ratio
      0
      Source IDH51-B34138A96B9F25F33C31FBB6
      Reference url count
      1
      Source IDH51-37F0AD63FC207ACF82F5373D
      Broken reference count
      0
      Source IDH51-ED86BFD695945C6D3B9A3E7E
      Point of use confirmation required
      true
      Source IDH51-BFE41A1EA7095075BA1250BA
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-BB1C1EB4731C3519365D5A7E

      Dosing source fields

      Id
      diltiazem
      Source IDH51-251A7F2D0ECBE05C141EADC7
      Generic name
      Diltiazem
      Source IDH51-C55E4120C527BD337722A060
      Coverage status
      direct_official_label_access_plus_local_snapshot
      Source IDH51-19A02E44B838DF41B32EE74D
      Package insert
      Query name
      Diltiazem
      Source IDH51-BAB412E7CAB59F558F9965D3
      Product and route must match
      true
      Source IDH51-D8E3F81DEC415347A0654273
      Live current label enabled
      false
      Source IDH51-9BD9EFA47CB1A1610269A4B3
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-C3090A096EF21A42CF1FC844
      Direct official label access enabled
      true
      Source IDH51-61D47F904767FEB5B333A803
      Outbound server request required
      false
      Source IDH51-EAA9571206145D3DCA8D9481
      Local summary status
      not_bundled
      Source IDH51-8A851FBC578E3966AFAB6F9E
      Clinical review
      Locally normalized
      false
      Source IDH51-CFBAF3CDFB3D777CFDD8BAD9
      Reviewed
      2026-08-29
      Source IDH51-E78783AE2E23EEB619009540
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-584D651885FB19C77632EEF6
      Clinical release verification
      Audit version
      3.4
      Source IDH51-C52418D3E05D33DFF9A88BCB
      Audited on
      2026-08-30
      Source IDH51-A58727361AD30378D13895DF
      Level
      amber
      Source IDH51-1FEBDD1181EBB8164A9D90FE
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-EE96EDDA8EE22FD643EC7B32
      Exact current label candidate
      false
      Source IDH51-FA32F9837A3A3FDECFDCC566
      Numeric support ratio
      0
      Source IDH51-A13A5B28131BA552E10E96F3
      Reference url count
      1
      Source IDH51-B693C708C545F3849F7F4A01
      Broken reference count
      0
      Source IDH51-0EA5A4311FADCE5363DC8FD1
      Point of use confirmation required
      true
      Source IDH51-D18BD6A4B3C3EAD8D376F0C9
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-6399F86EAE6BEC050B740C51
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      diltiazem
      Source IDH51-FF916FC1C0D3E13E29CBE391
      Name
      Diltiazem
      Source IDH51-BE72C6B2B40FBCDF71030AA2
      Brands
      Cardizem
      Source IDH51-903B20EF9F0107D8880588D6
      Therapeutic class
      Cardiovascular and vasoactive
      Source IDH51-6008E7633F03A631A7C705FF
      Review version
      3.1
      Source IDH51-0BEA84ACC4CAFD3D275AB141
      Review date
      2026-08-30
      Source IDH51-45697F099D03EC04993B7B54
      Release status
      structured_record_current_label_not_confirmed
      Source IDH51-E0918A33A271ADB9548EFD3E
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-ED59C1044FB8081D2CFDA1EB
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-4D8DB1D68235A4163A55FAD9
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-3E7C57198F1EF7779C6CBC07
      Reconstitution concentration
      Add concentrate to compatible solution or use premix.
      Source IDH51-106AFE413DA051F85A2E9C8B
      Maximum or recommended final concentration
      125 mg/125 mL (1 mg/mL)
      Source IDH51-4875740F0E2F8E264A085A8D
      Appropriate standardized containers
      125 mL
      Source IDH51-0BD3BE5129DD9B87223204C4
      Adult dosing range
      Common bag 125 mg 0.25 mg/kg first bolus; 0.35 mg/kg second bolus if indicated 5 to 10 mg/hour 0.25 mg/kg first bolus; 0.35 mg/kg second bolus if indicated
      Source IDH51-87D7F8A70C04492C8E494262
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-BBA958ABFDE03DD5CB592ACE
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-490FA08AB5C547AD48EF3678
      Infusion time
      5 to 15 mg/hour after bolus Over 2 minutes 5 to 10 mg/hour
      Source IDH51-582E84E1637555B760B3BDF4
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-144E07E49885B3C7B7A5DC9B
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-FAD9BAAC72FCC0B0422FDF8F
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-DC375D4694BC74A0E6048F2D
      Reconstitution concentration
      Primary
      existing_structured_record
      Source IDH51-1ED33BA946C2E67E0918E131
      Maximum or recommended final concentration
      Primary
      existing_structured_record
      Source IDH51-9AE218B3E7D1D9C76E0C3A50
      Appropriate standardized containers
      Primary
      existing_structured_record
      Source IDH51-071767E33E25068955A26656
      Adult dosing range
      Primary
      existing_structured_record
      Source IDH51-8C7363CA5E100D6C131AE940
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-3575A8DA3596B0B5754A9130
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-DB7F22E30ACA1FBB95AE4240
      Infusion time
      Primary
      existing_structured_record
      Source IDH51-A291AFB99CC3C30C97697B74
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-4E478A43B247F52228EC87E6
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-93CD9F3D0D2383450E52970C
      Population applicability
      Adult
      Applicability
      supported_or_source_present
      Source IDH51-6DAFE2A09C9F6EBBA0C63FDB
      Guide generation allowed
      true
      Source IDH51-0F636DE55CFBA1861564AB90
      Pediatric
      Applicability
      not_established
      Source IDH51-6233E7D1CA732829CE27D933
      Guide generation allowed
      false
      Source IDH51-B9269C13FC4D7DD372B240A1
      Neonatal
      Applicability
      not_established
      Source IDH51-E6DD86FB9CE456D319D15B82
      Guide generation allowed
      false
      Source IDH51-A5DCA3B02DA8EE209F166940
      Route presence
      Structured dilution
      true
      Source IDH51-EDFA04FBEE253685FDE47FE4
      Iv push
      true
      Source IDH51-BF2D384CB6D8EB755BE75C5F
      Continuous infusion
      true
      Source IDH51-6B65F490179E623CFEB9321A
      Pediatric source
      false
      Source IDH51-696F4B390A9DC889499063AD
      Neonatal source
      false
      Source IDH51-E32C593ED8DC10789EFD1024
      Legacy reference
      Status
      not_available
      Source IDH51-C62F85F7890DBCF217FC3158
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-6091AE2D2B1BB419C81B9BCE
      Concentration values detected
      HighUnitText
      Source IDH51-1B67356940AA0CCD9438C501
      1
      Source IDH51-508024B1F0637878E0EDC7C9
      		mg
      Source IDH51-104F5C535F337E2C829D58DD
      		1 mg/mL
      Source IDH51-8CA079911FF2D309BB5F126D
      Source files
      1. catalog.json
        Source IDH51-D420C74895238AB217701EAE
      2. dosing.json
        Source IDH51-602B1372A29A8EEBFD80132A
      3. legacy-map.json
        Source IDH51-24461345F1FE0E42837149CA
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-B48FF5CFF7FFE9010A9C9866
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-3B63A073F2FB8851F7522EBEcatalog.json
      /records/80/id      		Historical; current review incomplete
      H51-64B3066BDC1D687BA6A96B52catalog.json
      /records/80/generic_name      		Historical; current review incomplete
      H51-47AB7CA817F89AFC340695B5catalog.json
      /records/80/brand_names/0      		Historical; current review incomplete
      H51-BDBA39406FF672AEEC1F8677catalog.json
      /records/80/class      		Historical; current review incomplete
      H51-A7538F0D52D428C42ACEA2D7catalog.json
      /records/80/subclass      		Historical; current review incomplete
      H51-B31E9DABEE665B6EB987631Dcatalog.json
      /records/80/summary      		Historical; current review incomplete
      H51-7A8B9ECD046F507181AAB632catalog.json
      /records/80/common_uses/0      		Historical; current review incomplete
      H51-9294FC56A050FAF200EA7F7Fcatalog.json
      /records/80/common_uses/1      		Historical; current review incomplete
      H51-894A242AF77A8BCE78C8177Fcatalog.json
      /records/80/preparations/0      		Historical; current review incomplete
      H51-4F92BB792C5DA3F27FA1AD00catalog.json
      /records/80/preparations/0/population      		Historical; current review incomplete
      H51-CEB44268D857D33785A96FBDcatalog.json
      /records/80/preparations/0/amount      		Historical; current review incomplete
      H51-D37B717F8F6B24A14423917Acatalog.json
      /records/80/preparations/0/reconstitution      		Historical; current review incomplete
      H51-3FB41C040B662BA5ACDC4B6Ecatalog.json
      /records/80/preparations/0/diluent      		Historical; current review incomplete
      H51-30866CBA222158DDBA36FF54catalog.json
      /records/80/preparations/0/final_volume      		Historical; current review incomplete
      H51-B46F13A42A267B1E69F93B3Ecatalog.json
      /records/80/preparations/0/concentration      		Historical; current review incomplete
      H51-83683C27339A57DD2C4A3170catalog.json
      /records/80/preparations/0/rate      		Historical; current review incomplete
      H51-85DC3480CDB6D4766E50E949catalog.json
      /records/80/preparations/0/stability      		Historical; current review incomplete
      H51-BCC160C1D3B59E83792F8EC0catalog.json
      /records/80/preparations/0/notes      		Historical; current review incomplete
      H51-5E18093CF63570A4641A0AC9catalog.json
      /records/80/iv_push/0      		Historical; current review incomplete
      H51-7CA9C58A07EF48EBA7C95D46catalog.json
      /records/80/iv_push/0/population      		Historical; current review incomplete
      H51-F9E935596BD7923BC97DF109catalog.json
      /records/80/iv_push/0/dose_scope      		Historical; current review incomplete
      H51-5AB3C0CBE52F634B3B30500Ccatalog.json
      /records/80/iv_push/0/concentration      		Historical; current review incomplete
      H51-4E6B49B8B8C756E6AF833CAEcatalog.json
      /records/80/iv_push/0/rate      		Historical; current review incomplete
      H51-168AFC2966BF961AD7926604catalog.json
      /records/80/iv_push/0/status      		Historical; current review incomplete
      H51-5EA2290440BF65C570954D9Ccatalog.json
      /records/80/iv_push/0/notes      		Historical; current review incomplete
      H51-CDD6CDCAD74BFFE2CD835C20catalog.json
      /records/80/continuous_infusions/0      		Historical; current review incomplete
      H51-AD0257DB2F74E726B7B5245Dcatalog.json
      /records/80/continuous_infusions/0/population      		Historical; current review incomplete
      H51-30535B4D7529A2BF2A7B9A88catalog.json
      /records/80/continuous_infusions/0/standard_concentration      		Historical; current review incomplete
      H51-907584463051B36A81E9F617catalog.json
      /records/80/continuous_infusions/0/initial_rate      		Historical; current review incomplete
      H51-0BC71D03B909FA4D4E35F4B4catalog.json
      /records/80/continuous_infusions/0/titration      		Historical; current review incomplete
      H51-1B30AA2180298B8B0C2ADF09catalog.json
      /records/80/continuous_infusions/0/maximum      		Historical; current review incomplete
      H51-1B61B43C30A57E5A62DC4DCDcatalog.json
      /records/80/continuous_infusions/0/notes      		Historical; current review incomplete
      H51-06DA9F5033092875461CAA63catalog.json
      /records/80/warnings/0      		Historical; current review incomplete
      H51-EA45F38C6A2DF81BF9FE8E37catalog.json
      /records/80/warnings/1      		Historical; current review incomplete
      H51-A920907EE62A8F06B57FA4EAcatalog.json
      /records/80/monitoring/0      		Historical; current review incomplete
      H51-9F06596BF9845C40D919BAEFcatalog.json
      /records/80/monitoring/1      		Historical; current review incomplete
      H51-7DBAA6310DB9BDB4D3569837catalog.json
      /records/80/monitoring/2      		Historical; current review incomplete
      H51-151C220FD94B7D4F755E6BBAcatalog.json
      /records/80/populations/0      		Historical; current review incomplete
      H51-EDD74232823C6A30757D8210catalog.json
      /records/80/evidence_tier      		Historical; current review incomplete
      H51-2E8B62DCF732AD99BCF4CC33catalog.json
      /records/80/high_alert      		Historical; current review incomplete
      H51-59D025CEBB2219FF5361BA3Ccatalog.json
      /records/80/hazardous      		Historical; current review incomplete
      H51-86D54DF9649822E5D580918Bcatalog.json
      /records/80/status      		Historical; current review incomplete
      H51-BCE032411DFEB5CF81B44110catalog.json
      /records/80/reviewed      		Historical; current review incomplete
      H51-686005CDA7C7A5D10931FC22catalog.json
      /records/80/version_added      		Historical; current review incomplete
      H51-A61C93F7618D7CADC28F02B1catalog.json
      /records/80/sources/0      		Historical; current review incomplete
      H51-13E5828B5919FCFDB0C7DAD6catalog.json
      /records/80/sources/0/label      		Historical; current review incomplete
      H51-45B758C5EB10FA6C4AEC3558catalog.json
      /records/80/sources/0/url      		Historical; current review incomplete
      H51-8F25921C5E55616463938299catalog.json
      /records/80/sources/0/kind      		Historical; current review incomplete
      H51-E9BEA47B9D3BD48AC043953Acatalog.json
      /records/80/sources/1      		Historical; current review incomplete
      H51-7D0CF3CAF5961A4105246DF3catalog.json
      /records/80/sources/1/label      		Historical; current review incomplete
      H51-7EFDC2D363166632BC4F23E2catalog.json
      /records/80/sources/1/url      		Historical; current review incomplete
      H51-01345D68DEE568837B658F2Acatalog.json
      /records/80/sources/1/kind      		Historical; current review incomplete
      H51-182710E2A3E5DA3D86082E43catalog.json
      /records/80/legacy_title      		Historical; current review incomplete
      H51-DE89F0FB3C522FC76EA4386Acatalog.json
      /records/80/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-81DCD827A147A2CE3072B164catalog.json
      /records/80/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-15244A997AC1279B8FCDC03Bcatalog.json
      /records/80/clinical_release_verification/level      		Historical; current review incomplete
      H51-9AC5C98230D7645D28C63EE5catalog.json
      /records/80/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-BCCBF428872FB633E2E0D4AFcatalog.json
      /records/80/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-8B67E18C246CB826E1D26934catalog.json
      /records/80/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-A6ED1308ED0DEE84E995E9A2catalog.json
      /records/80/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-B34138A96B9F25F33C31FBB6catalog.json
      /records/80/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-37F0AD63FC207ACF82F5373Dcatalog.json
      /records/80/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-ED86BFD695945C6D3B9A3E7Ecatalog.json
      /records/80/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-BFE41A1EA7095075BA1250BAcatalog.json
      /records/80/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-BB1C1EB4731C3519365D5A7Ecatalog.json
      /records/80/clinical_release_verification/note      		Historical; current review incomplete
      H51-55673F8512E7682EEFFD05B1catalog.json
      /records/80/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-251A7F2D0ECBE05C141EADC7dosing.json
      /records/80/id      		Historical; current review incomplete
      H51-C55E4120C527BD337722A060dosing.json
      /records/80/generic_name      		Historical; current review incomplete
      H51-19A02E44B838DF41B32EE74Ddosing.json
      /records/80/coverage_status      		Historical; current review incomplete
      H51-BAB412E7CAB59F558F9965D3dosing.json
      /records/80/package_insert/query_name      		Historical; current review incomplete
      H51-DD361BB735AB99181C2889E9dosing.json
      /records/80/package_insert/preferred_setid      		Historical; current review incomplete
      H51-D8E3F81DEC415347A0654273dosing.json
      /records/80/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-9BD9EFA47CB1A1610269A4B3dosing.json
      /records/80/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-C3090A096EF21A42CF1FC844dosing.json
      /records/80/package_insert/source_priority      		Historical; current review incomplete
      H51-61D47F904767FEB5B333A803dosing.json
      /records/80/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-EAA9571206145D3DCA8D9481dosing.json
      /records/80/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-8A851FBC578E3966AFAB6F9Edosing.json
      /records/80/package_insert/local_summary_status      		Historical; current review incomplete
      H51-A239F239096BA9B82A3F22FDdosing.json
      /records/80/renal/classification      		Historical; current review incomplete
      H51-5F01A0D3A6B697F45A5E7BAAdosing.json
      /records/80/renal/summary      		Historical; current review incomplete
      H51-6A3CB7B618F497E12F8D27BFdosing.json
      /records/80/renal/method_note      		Historical; current review incomplete
      H51-1C270C8E5A98B9B435A92001dosing.json
      /records/80/existing_route_snapshots/0      		Historical; current review incomplete
      H51-FACBFF6353B67369F61D50DDdosing.json
      /records/80/existing_route_snapshots/0/route      		Historical; current review incomplete
      H51-DDAE0A8391A6B620DAE4D703dosing.json
      /records/80/existing_route_snapshots/0/population      		Historical; current review incomplete
      H51-52B6D8245A2BA7FF2CE3C20Adosing.json
      /records/80/existing_route_snapshots/0/indication      		Historical; current review incomplete
      H51-6DBB71BD1BEF4D45EFD6FFF2dosing.json
      /records/80/existing_route_snapshots/0/dose      		Historical; current review incomplete
      H51-D6B6812FF0B5E5160874AAB3dosing.json
      /records/80/existing_route_snapshots/0/interval      		Historical; current review incomplete
      H51-994EBC532C11F1DB48CCC234dosing.json
      /records/80/existing_route_snapshots/0/duration      		Historical; current review incomplete
      H51-3AE297A366C01B16D7DF85E0dosing.json
      /records/80/existing_route_snapshots/0/administration      		Historical; current review incomplete
      H51-F45CBC843061B94B0C92A402dosing.json
      /records/80/existing_route_snapshots/0/source_level      		Historical; current review incomplete
      H51-ED353FE7186C6C405C355E80dosing.json
      /records/80/existing_route_snapshots/0/notes      		Historical; current review incomplete
      H51-B7649B3509EA42F3723C7F22dosing.json
      /records/80/existing_route_snapshots/1      		Historical; current review incomplete
      H51-C27F3449839FCD19E13F5CA6dosing.json
      /records/80/existing_route_snapshots/1/route      		Historical; current review incomplete
      H51-101E53C2431CF39263AB40EAdosing.json
      /records/80/existing_route_snapshots/1/population      		Historical; current review incomplete
      H51-090344C2C507C6C272247AE0dosing.json
      /records/80/existing_route_snapshots/1/indication      		Historical; current review incomplete
      H51-FA1FF1566F83BEAC33E4A327dosing.json
      /records/80/existing_route_snapshots/1/dose      		Historical; current review incomplete
      H51-CC51EED7970E14446C614158dosing.json
      /records/80/existing_route_snapshots/1/interval      		Historical; current review incomplete
      H51-5A5D34CEA00C14E87106793Edosing.json
      /records/80/existing_route_snapshots/1/duration      		Historical; current review incomplete
      H51-E5B81E9F078B23F862BA2C5Cdosing.json
      /records/80/existing_route_snapshots/1/administration      		Historical; current review incomplete
      H51-542409850CBBD695008F2E19dosing.json
      /records/80/existing_route_snapshots/1/source_level      		Historical; current review incomplete
      H51-726578B89F9A49156D412A3Cdosing.json
      /records/80/existing_route_snapshots/1/notes      		Historical; current review incomplete
      H51-08FE545C06B0CCEE38B486DCdosing.json
      /records/80/existing_route_snapshots/2      		Historical; current review incomplete
      H51-0E737CCA1A11F57CC29CCB00dosing.json
      /records/80/existing_route_snapshots/2/route      		Historical; current review incomplete
      H51-1AF18422211B90A9E4799500dosing.json
      /records/80/existing_route_snapshots/2/population      		Historical; current review incomplete
      H51-21AD94F02D914D784D65EBEEdosing.json
      /records/80/existing_route_snapshots/2/indication      		Historical; current review incomplete
      H51-255F225CBA87213584ECA126dosing.json
      /records/80/existing_route_snapshots/2/dose      		Historical; current review incomplete
      H51-5A3080819E1E35AA2B702828dosing.json
      /records/80/existing_route_snapshots/2/interval      		Historical; current review incomplete
      H51-0E3207506ECFFFE28D352C92dosing.json
      /records/80/existing_route_snapshots/2/duration      		Historical; current review incomplete
      H51-29E2C6D8C3306AC0AE111248dosing.json
      /records/80/existing_route_snapshots/2/administration      		Historical; current review incomplete
      H51-3DF29544A3656453ED7A5F6Ddosing.json
      /records/80/existing_route_snapshots/2/source_level      		Historical; current review incomplete
      H51-F9FB8CF63D1DDC89095C14C8dosing.json
      /records/80/existing_route_snapshots/2/notes      		Historical; current review incomplete
      H51-CFBAF3CDFB3D777CFDD8BAD9dosing.json
      /records/80/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-E78783AE2E23EEB619009540dosing.json
      /records/80/clinical_review/reviewed      		Historical; current review incomplete
      H51-584D651885FB19C77632EEF6dosing.json
      /records/80/clinical_review/status      		Historical; current review incomplete
      H51-C52418D3E05D33DFF9A88BCBdosing.json
      /records/80/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-A58727361AD30378D13895DFdosing.json
      /records/80/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-1FEBDD1181EBB8164A9D90FEdosing.json
      /records/80/clinical_release_verification/level      		Historical; current review incomplete
      H51-EE96EDDA8EE22FD643EC7B32dosing.json
      /records/80/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-FA32F9837A3A3FDECFDCC566dosing.json
      /records/80/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-0021B4DF8FE3F8AC3E3916A7dosing.json
      /records/80/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-6D9587AED0F11A3E9F85EB82dosing.json
      /records/80/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-A13A5B28131BA552E10E96F3dosing.json
      /records/80/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-B693C708C545F3849F7F4A01dosing.json
      /records/80/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-0EA5A4311FADCE5363DC8FD1dosing.json
      /records/80/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-D18BD6A4B3C3EAD8D376F0C9dosing.json
      /records/80/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-6399F86EAE6BEC050B740C51dosing.json
      /records/80/clinical_release_verification/note      		Historical; current review incomplete
      H51-E688C078BD84A227C38FE606dosing.json
      /records/80/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-85322D40A0988000C9A1AB83first-look-v5.1.json
      /records/80/id      		Historical; current review incomplete
      H51-D6957EB5B768EB04AC5553F1first-look-v5.1.json
      /records/80/generic_name      		Historical; current review incomplete
      H51-84E0F91DCDB6360AE0BE7FD7first-look-v5.1.json
      /records/80/class      		Historical; current review incomplete
      H51-B6C6253764BEBBE2BD4D234Cfirst-look-v5.1.json
      /records/80/subclass      		Historical; current review incomplete
      H51-EFE04100B3ABEE1BD4454B4Bfirst-look-v5.1.json
      /records/80/primary_uses/0      		Historical; current review incomplete
      H51-FC6083CD598029218480CDF5first-look-v5.1.json
      /records/80/primary_uses/1      		Historical; current review incomplete
      H51-F36EF4A84BE70AAE88A2D2BAfirst-look-v5.1.json
      /records/80/mechanism      		Historical; current review incomplete
      H51-EFE049950E9527B20BC5FA99first-look-v5.1.json
      /records/80/mechanism_level      		Historical; current review incomplete
      H51-CC87F70F82049BBE8E8F5840first-look-v5.1.json
      /records/80/basic_dosing_orientation      		Historical; current review incomplete
      H51-71AD0330B5C2017175739170first-look-v5.1.json
      /records/80/administration_orientation      		Historical; current review incomplete
      H51-4A9B974646C28D676A785160first-look-v5.1.json
      /records/80/renal_and_population_orientation      		Historical; current review incomplete
      H51-191EF70A7CC522A1046EC7AFfirst-look-v5.1.json
      /records/80/key_safety_orientation/0      		Historical; current review incomplete
      H51-7F88768F26013127A8EA82C6first-look-v5.1.json
      /records/80/key_safety_orientation/1      		Historical; current review incomplete
      H51-C69FDC27EEFB322CD38A63F3first-look-v5.1.json
      /records/80/coverage_path      		Historical; current review incomplete
      H51-44068C8620818385072D67C1first-look-v5.1.json
      /records/80/coverage_path_label      		Historical; current review incomplete
      H51-8D3D71E63F601B4BB0162B2Dfirst-look-v5.1.json
      /records/80/official_label_url      		Historical; current review incomplete
      H51-CDFFE1C8E8F579FB81CB5970first-look-v5.1.json
      /records/80/legacy_title      		Historical; current review incomplete
      H51-3CB788F3F33DE66F26D5A75Bfirst-look-v5.1.json
      /records/80/review_note      		Historical; current review incomplete
      H51-7D795909AB365512025AE0D0first-look-v5.1.json
      /records/80/search_text      		Historical; current review incomplete
      H51-E9A1BA6175583C43F060F9E2first-look-v5.1.json
      /records/80/official_search_url      		Historical; current review incomplete
      H51-C794DABE745364C1F059FD61first-look-v5.1.json
      /records/80/official_access_mode      		Historical; current review incomplete
      H51-D68A1134BC0F853A96F411C0first-look-v5.1.json
      /records/80/official_access_url      		Historical; current review incomplete
      H51-5EDA07026A9A3166C03CEC28first-look-v5.1.json
      /records/80/official_search_query      		Historical; current review incomplete
      H51-6435557ABCA418B9C02117A5first-look-v5.1.json
      /records/80/official_access_reason      		Historical; current review incomplete
      H51-FF916FC1C0D3E13E29CBE391preparation-assessments-v3.8.json
      /80/id      		Historical; current review incomplete
      H51-BE72C6B2B40FBCDF71030AA2preparation-assessments-v3.8.json
      /80/name      		Historical; current review incomplete
      H51-903B20EF9F0107D8880588D6preparation-assessments-v3.8.json
      /80/brands      		Historical; current review incomplete
      H51-6008E7633F03A631A7C705FFpreparation-assessments-v3.8.json
      /80/therapeutic_class      		Historical; current review incomplete
      H51-0BEA84ACC4CAFD3D275AB141preparation-assessments-v3.8.json
      /80/review_version      		Historical; current review incomplete
      H51-45697F099D03EC04993B7B54preparation-assessments-v3.8.json
      /80/review_date      		Historical; current review incomplete
      H51-E0918A33A271ADB9548EFD3Epreparation-assessments-v3.8.json
      /80/release_status      		Historical; current review incomplete
      H51-ED59C1044FB8081D2CFDA1EBpreparation-assessments-v3.8.json
      /80/market_status/status      		Historical; current review incomplete
      H51-4D8DB1D68235A4163A55FAD9preparation-assessments-v3.8.json
      /80/market_status/basis      		Historical; current review incomplete
      H51-3E7C57198F1EF7779C6CBC07preparation-assessments-v3.8.json
      /80/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-106AFE413DA051F85A2E9C8Bpreparation-assessments-v3.8.json
      /80/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-4875740F0E2F8E264A085A8Dpreparation-assessments-v3.8.json
      /80/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-0BD3BE5129DD9B87223204C4preparation-assessments-v3.8.json
      /80/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-87D7F8A70C04492C8E494262preparation-assessments-v3.8.json
      /80/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-BBA958ABFDE03DD5CB592ACEpreparation-assessments-v3.8.json
      /80/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-490FA08AB5C547AD48EF3678preparation-assessments-v3.8.json
      /80/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-582E84E1637555B760B3BDF4preparation-assessments-v3.8.json
      /80/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-144E07E49885B3C7B7A5DC9Bpreparation-assessments-v3.8.json
      /80/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-48A060059336C68DF14CD215preparation-assessments-v3.8.json
      /80/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-BBE1B7D67499F85F9B0B5EE6preparation-assessments-v3.8.json
      /80/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-CCF55F813168CC081D6CB1C8preparation-assessments-v3.8.json
      /80/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-41DCF0F76A0439FDAA46DAAEpreparation-assessments-v3.8.json
      /80/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-FAD9BAAC72FCC0B0422FDF8Fpreparation-assessments-v3.8.json
      /80/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-70A1ABC747B134968CB485F0preparation-assessments-v3.8.json
      /80/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-DC375D4694BC74A0E6048F2Dpreparation-assessments-v3.8.json
      /80/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-1ED33BA946C2E67E0918E131preparation-assessments-v3.8.json
      /80/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-9AE218B3E7D1D9C76E0C3A50preparation-assessments-v3.8.json
      /80/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-071767E33E25068955A26656preparation-assessments-v3.8.json
      /80/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-8C7363CA5E100D6C131AE940preparation-assessments-v3.8.json
      /80/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-3575A8DA3596B0B5754A9130preparation-assessments-v3.8.json
      /80/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-DB7F22E30ACA1FBB95AE4240preparation-assessments-v3.8.json
      /80/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-A291AFB99CC3C30C97697B74preparation-assessments-v3.8.json
      /80/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-4E478A43B247F52228EC87E6preparation-assessments-v3.8.json
      /80/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-93CD9F3D0D2383450E52970Cpreparation-assessments-v3.8.json
      /80/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-6DAFE2A09C9F6EBBA0C63FDBpreparation-assessments-v3.8.json
      /80/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-0F636DE55CFBA1861564AB90preparation-assessments-v3.8.json
      /80/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-6233E7D1CA732829CE27D933preparation-assessments-v3.8.json
      /80/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-B9269C13FC4D7DD372B240A1preparation-assessments-v3.8.json
      /80/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-E6DD86FB9CE456D319D15B82preparation-assessments-v3.8.json
      /80/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-A5DCA3B02DA8EE209F166940preparation-assessments-v3.8.json
      /80/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-EDFA04FBEE253685FDE47FE4preparation-assessments-v3.8.json
      /80/route_presence/structured_dilution      		Historical; current review incomplete
      H51-BF2D384CB6D8EB755BE75C5Fpreparation-assessments-v3.8.json
      /80/route_presence/iv_push      		Historical; current review incomplete
      H51-6B65F490179E623CFEB9321Apreparation-assessments-v3.8.json
      /80/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-696F4B390A9DC889499063ADpreparation-assessments-v3.8.json
      /80/route_presence/pediatric_source      		Historical; current review incomplete
      H51-E32C593ED8DC10789EFD1024preparation-assessments-v3.8.json
      /80/route_presence/neonatal_source      		Historical; current review incomplete
      H51-C62F85F7890DBCF217FC3158preparation-assessments-v3.8.json
      /80/legacy_reference/status      		Historical; current review incomplete
      H51-6091AE2D2B1BB419C81B9BCEpreparation-assessments-v3.8.json
      /80/label_resolution/status      		Historical; current review incomplete
      H51-1B67356940AA0CCD9438C501preparation-assessments-v3.8.json
      /80/concentration_values_detected/0      		Historical; current review incomplete
      H51-B9183B81329A9D0FA7BB778Fpreparation-assessments-v3.8.json
      /80/concentration_values_detected/0/low      		Historical; current review incomplete
      H51-508024B1F0637878E0EDC7C9preparation-assessments-v3.8.json
      /80/concentration_values_detected/0/high      		Historical; current review incomplete
      H51-104F5C535F337E2C829D58DDpreparation-assessments-v3.8.json
      /80/concentration_values_detected/0/unit      		Historical; current review incomplete
      H51-8CA079911FF2D309BB5F126Dpreparation-assessments-v3.8.json
      /80/concentration_values_detected/0/text      		Historical; current review incomplete
      H51-D420C74895238AB217701EAEpreparation-assessments-v3.8.json
      /80/source_files/0      		Historical; current review incomplete
      H51-602B1372A29A8EEBFD80132Apreparation-assessments-v3.8.json
      /80/source_files/1      		Historical; current review incomplete
      H51-24461345F1FE0E42837149CApreparation-assessments-v3.8.json
      /80/source_files/2      		Historical; current review incomplete
      H51-B48FF5CFF7FFE9010A9C9866preparation-assessments-v3.8.json
      /80/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top